Arvinas has announced a multi-year strategic collaboration with Merck Sharp & Dohme encompassing multiple disease targets across several therapeutic areas. Arvina’s novel proteolysis-targeting chimeras (PROTAC) technology, bifunctional small molecules that target proteins for degradation and removal from a cell

Arvinas will receive an up-front payment and funding to support Merck-related research. Additionally, Arvinas could earn up to $434 million if all research, development, regulatory and commercial milestone payments are successfully paid for products against all the targets initially selected by Merck, as well as tiered royalties. Merck may, at its discretion, elect to expand the collaboration to include additional disease targets.